The stock of Gracell Biotechnologies Inc. (NASDAQ:GRCL) last traded at $2.14, down -1.83% from the previous session.
Data from the available sources indicates that Gracell Biotechnologies Inc. (NASDAQ:GRCL) is covered by 7 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $7.00, we find $12.00. Given the previous closing price of $2.18, this indicates a potential upside of 450.46 percent. GRCL stock price is now -21.79% away from the 50-day moving average and -30.64% away from the 200-day moving average. The market capitalization of the company currently stands at $141.54M.
In total, 0 analysts have assigned it a hold rating, and 7 have given it a buy rating. Brokers who have rated the stock have averaged $14.29 as their price target over the next twelve months.
With the price target of $6, H.C. Wainwright recently initiated with Buy rating for Gracell Biotechnologies Inc. (NASDAQ: GRCL). On September 22, 2022, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $12, while ‘Wells Fargo’ rates the stock as ‘Overweight’.
A total of 7.89% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GRCL stock. A new stake in Gracell Biotechnologies Inc. shares was purchased by GREAT POINT PARTNERS I LP during the first quarter worth $961,000. BALYASNY ASSET MANAGEMENT LLC invested $53,000 in shares of GRCL during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in Gracell Biotechnologies Inc. valued at approximately $8,000. CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. acquired a new stake in GRCL for approximately $1,000. In total, there are 49 active investors with 45.50% ownership of the company’s stock.
With an opening price of $2.1200 on Tuesday morning, Gracell Biotechnologies Inc. (NASDAQ: GRCL) set off the trading day. During the past 12 months, Gracell Biotechnologies Inc. has had a low of $1.68 and a high of $5.69. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 6.80, and a quick ratio of 6.80. The fifty day moving average price for GRCL is $2.7362 and a two-hundred day moving average price translates $3.0854 for the stock.
The latest earnings results from Gracell Biotechnologies Inc. (NASDAQ: GRCL) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.3, missing analysts’ expectations of -$0.07 by -0.23. This compares to -$0.30 EPS in the same period last year. For the current quarter, analysts expect GRCL to generate $20k in revenue.
Gracell Biotechnologies Inc.(GRCL) Company Profile
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People’s Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin’s lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company’s product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.